Tempest Therapeutics Adjourns Special Meeting After Failing to Secure Supermajority Vote on Governance Changes
TPST is trading near its 52-week low of $0.87 (1.1% below the low).
Summary
Tempest Therapeutics adjourned its special meeting to August 17 after failing to get the 75% supermajority needed to replace supermajority voting requirements and permit written consent. Only 67.7% of shares were represented, and the company has hired a proxy solicitor to help secure votes.
Key Events · Corporate Governance and Compliance · TPST
-
Special Meeting Adjourned
The special meeting convened July 27, 2026 was adjourned to August 17, 2026 after failing to secure the 75% supermajority vote required to approve a Certificate of Amendment to replace supermajority voting requirements and permit stockholder action by written consent.
-
Vote Shortfall
Only 10,031,446 shares (67.7% of the 14,806,997 outstanding) were represented, falling short of the 75% affirmative vote threshold needed from all shares entitled to vote.
-
Proxy Solicitor Engaged
The company has engaged Sodali & Co., a proxy solicitation firm, to assist in obtaining adequate votes for the reconvened meeting, signaling urgency and potential difficulty in rallying shareholder support.
-
Governance Red Flag
The inability to pass a routine governance proposal, combined with a going-concern warning, Nasdaq deficiency notices, and a stock near its 52-week low, suggests deep shareholder disengagement or opposition.
Analysis · TPST · Life Sciences
Tempest Therapeutics failed to get the required 75% supermajority vote to replace its supermajority voting requirements and allow stockholder action by written consent. Only 67.7% of shares were represented, and the company adjourned the meeting to August 17, 2026. This is a governance red flag — the inability to pass a routine governance proposal signals deep shareholder disengagement or opposition, especially against a backdrop of a going-concern warning, Nasdaq deficiency notices, and a stock trading near its 52-week low. The company has hired a proxy solicitor, indicating urgency and potential difficulty in rallying votes.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 37.1% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.72%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.9M. The 52-week trading range was $0.87 to $12.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.